AstraZeneca has announced a historic investment of $50 billion in the United States by 2030, with a focus on chronic diseases and innovation. The company’s largest single manufacturing investment will be located in Virginia, creating tens of thousands of new jobs across the country.
The proposed multi-billion dollar drug substance manufacturing center will produce substances for AstraZeneca’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, and combination small molecule products. The facility, set to open in Virginia, will utilize AI, automation, and data analytics to optimize production.
AstraZeneca’s investment is part of its broader ambition to reach $80 billion in total revenue by 2030, with 50% expected to be generated in the US. This represents a significant increase from its current market share, currently at 42%.
The company’s US investments will include expansion of R&D facilities, state-of-the-art centers for cell therapy, and specialty manufacturing sites. These projects are expected to create hundreds of jobs and strengthen the country’s domestic supply chain.
“We’re proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores,” said Howard Lutnick, US Secretary of Commerce. “This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”
Governor Glenn Youngkin also praised the investment, stating that it sets a new standard for pharmaceutical manufacturing technology and will further strengthen Virginia’s economy.
AstraZeneca’s commitment to innovation and patient care has been recognized globally. The company employs over 18,000 people in the US and supports 92,000 jobs overall across the country.
Source: https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-plans-to-invest-50-billion-in-America-for-medicines-manufacturing-and-R-and-D.html